- AGC Biologics has entered a partnership with Quell Therapeutics to provide lentiviral vector material for Treg cell therapy drug candidates.
- The collaboration supports CTA/IND submissions using AGC Biologics’ ProntoLVV™ platform from its Milan Cell and Gene Center of Excellence.
AGC Biologics has announced a new partnership with Quell Therapeutics, a clinical-stage biotechnology company developing T-regulatory (Treg) cell therapies for severe immune disorders. The collaboration will see AGC Biologics supply lentiviral vector (LVV) material using its proprietary ProntoLVV™ platform to support Quell’s pipeline of drug candidates ahead of clinical trial applications.
Under the agreement, AGC Biologics’ Milan Cell and Gene Center of Excellence is producing LVV materials for use in Quell’s cell therapies. The platform incorporates Quell’s gene of interest into standardised production processes using off-the-shelf materials, enabling both suspension and adhesion systems. The approach is designed to ensure GMP readiness and facilitate a smooth transition to clinical trial manufacturing.
“Our ProntoLVV platform is well-suited to support Quell in advancing its Treg cell therapies toward clinical trials,” said Luca Alberici, Executive Vice President, Global Cell & Gene Technologies at AGC Biologics.
Quell’s therapies aim to restore immune balance in patients suffering from immune and inflammatory conditions. According to Aaron Vernon, Chief Manufacturing Officer at Quell Therapeutics, “AGC Biologics provides the reliability, speed and efficiency we need as we prepare our Treg therapies for clinical trials.”
The Milan facility brings 30 years of experience in cell and gene therapy manufacturing and holds commercial authorisations from both the FDA and EMA. AGC Biologics’ Cell and Gene Technologies Division aims to reduce costs and development timelines while maintaining high-quality CDMO standards for viral vectors and advanced therapies.
Stay ahead of trends and best practices
